Biovalley Launches Second Round of Equity Crowdfunding

Biovalley Investments Partner SpA (BIP) has launched its second equity crowdfunding campaign on the CrowdFundMe platform, with a minimum collection target of €250,000 and a pre-money valuation set at €17,569,062.

This new round is part of a process already underway, aimed at strengthening the group’s industrial positioning and supporting the scalability of its activities in the healthcare sector.

The previous campaign, which concluded in January 2020, had raised $1.65 million against a pre-money valuation of $10 million.

Biovalley was created from research to become an industry

Biovalley Investments Partners is a healthcare industry group that transforms biotech, pharmaceutical, and digital technologies into concrete solutions for hospitals, clinics, and healthcare companies.

The group is based in Trieste, one of Europe’s most advanced scientific hubs, where the number of researchers is four times higher than the EU/US average: an environment that favors the rapid development of Deep Tech technologies and their market introduction.

BIP’s model involves injecting innovations—robotics, biotech, and artificial intelligence—into existing SMEs, accelerating their growth, scalability, and the speed with which they bring new products to market.

Two integrated strategic areas

The Biovalley group works in two complementary areas: on the one hand, the BioTech & Pharma division, which deals with orphan drugs, biosimilars and the development and production of APIs (active pharmaceutical ingredients).

On the other hand, the BioICT division, focused on hospital robotics, medical software and AI solutions for healthcare facilities.

This dual focus allows BIP to transversally cover the entire spectrum of medical and healthcare innovation, combining research, technological development and industrial application.

Biovalley’s business model, revenue sources, and milestones already achieved

In the field of hospital robotics, the company has developed and patented (in the EU, USA and China) the ChemoMaker® robot, which automates the preparation of chemotherapy without requiring infrastructural modifications to the departments.

To date, 23 devices have been sold in seven European countries. Biovalley’s revenues come from the sale of the robot, patented consumables, and maintenance services.

On the orphan drug front, Biovalley has won 11 three-year hospital tenders, with revenues deriving from supplies to public and private hospitals.

As for insulin biosimilars, the biotech platform developed with the support of the ICGEB foresees revenues from licensing, third-party manufacturing, and collaborations.

Finally, the healthcare software and AI sector has already served over 270 facilities, including laboratories, clinics, and nursing homes, generating revenue from software licenses, annual fees, and AI services on proprietary infrastructure.

In terms of numbers, the value of production grew from €8.4 million to €11.7 million between 2020 and 2024, EBITDA from €0.5 million to €1.7 million, and the NFP improved by 26% thanks also to the sale of the subsidiary ICT Logic for €1.8 million.

The consolidated industrial portfolio includes active patents and over 18 completed M&A transactions, with an expanding commercial presence in Western Europe and new entries in Eastern Europe.

Future prospects for Biovalley

The CrowdFundMe campaign is part of a broader strategy that includes a possible listing or acquisition as the next step.

The management team, with its proven experience in the sector, is targeting a strategic exit through a global player or a regulated stock exchange, positioning the group as a high-potential target.

The combination of hospital robotics, orphan drugs, biosimilars, and healthcare AI allows Biovalley to leverage multiple growth levers, with diversified and scalable revenues.

With its second campaign on CrowdFundMe, the company intends to “strengthen its development trajectory and invites the investment community to participate in a story that unites innovation, healthcare and business.”

__

(Featured image by Severinson via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.